First Generic Versions of Singulair Approved
FRIDAY, Aug. 3 (HealthDay News) -- The first generic versions of Singulair (montelukast sodium) have been approved by the U.S. Food and Drug Administration.
The product is not meant to treat sudden onset of serious asthma symptoms, the FDA warned, but it does treat asthma and hay fever symptoms by blocking substances in the body called leukotrienes, the agency said Friday in a news release.
The FDA said the product could cause serious side effects, including behavioral or mood changes, depression, hallucinations, upper respiratory infection, or feeling numbness in the extremities. Anyone who has these symptoms should immediately see a physician, the agency said.
Less serious but more common adverse reactions could include: fever, headache, sore throat, cough, stomach pain, diarrhea, ear ache or runny nose.
Approval to produce generic tablets, generic chewable tablets or both versions was granted to: Apotex Inc., Aurobindo Pharma, Endo Pharmaceuticals, Glenmark Generics, Kudco Ireland Inc., Mylan Inc., Roxane Laboratories, Sandoz Inc., Teva Pharmaceuticals Inc., and Torrent Pharmaceuticals, the FDA said.
The agency stressed the generic drugs it approves are equal in strength and quality to their brand-name counterparts.
Brand-name Singulair, made by Merck & Co., was approved by the FDA in 1998.
Medline Plus has more about this drug.Related Articles
- Sovaldi Approved for Chronic Hepatitis C
December 09, 2013
- Nebulizers May Not Deliver Full Drug Dose to Kids With Asthma
December 06, 2013
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.